p16INK4a/Ki-67 dual stain cytology for cervical cancer screening in Thika district, Kenya

The identification of suited early detection tests is one among the multiple requirements to reduce cervical cancer incidence in developing countries. We evaluated p16INK4a/Ki-67 dual-stain cytology in a screening population in Thika district, Kenya and compared it to high-risk human papillomavirus (HR-HPV) DNA testing and visual inspection by acetic acid (VIA) and Lugol’s iodine (VILI). Valid results for all tests could be obtained in 477 women. 20.9 % (100/477) were tested positive for HR-HPV DNA, 3.1 % (15/477) had positive VIA/VILI and 8.2 % (39/477) positive p16INK4a/Ki-67 cytology. Of 22 women that showed up for colposcopy and biopsy, 6 women were diagnosed with CIN3 and two with CIN2. All women with CIN2/3 were negative in VIA/VILI screening and positive by HR-HPV DNA testing. But HPV was also positive in 91.7 % (11/12) of women with normal histology. p16INK4a/Ki-67 cytology was positive in all 6 women with CIN3, in one of the two CIN2 and in only 8.3 % (1/12) of women with normal histology. p16INK4a/Ki-67 cytology is an interesting test for further studies in developing countries, since our findings point to a lower fraction of false positive test results using p16INK4a/Ki-67 cytology compared to HPV DNA testing in a Kenyan screening population. VIA/VILI missed all histology-proven CIN2/3.


Background
Cancer of the uterine cervix is the third most common cancer in women around the world and still the leading cancer in women in Sub Sahara Africa [1]. Of the 450,000 new cases every year, over 80 % occur in resource poor countries [1]. In Kenya, the annual crude incidence rate of cervical cancer is 16.5 per 100,000 women with a leading mortality rate of 13.5 in 100,000 women [1,2]. Implementation of nationwide screening for cervical cancer has been successful in reducing the incidence and mortality rates of cervical cancer in many countries [3]. A further reduction in disease incidence is suggested to be reached by prophylactic HPV vaccinations, if they are combined with continued screening [4]. However, screening and vaccination coverage in developing countries is dramatically low. In Kenya, only 3.2 % of the female population aged 18-69 have been screened for cervical cancer [2].
Cervical cancer is caused by long lasting infections of the cervical squamous cell epithelium with human papillomaviruses (HPV). The infection is usually acquired during adolescence when women become sexually active and infection prevalence my reach over 50 % [5]. While the vast majority of women clear the infection, upon persistent HPV infections premalignant alterations (cervical intraepithelial neoplasia, CIN) may occur after several years, which precede the development of cervical cancer. Cervical cancer is largely preventable by detecting premalignant alterations and treat them by ablation or excisional means [5].
Currently the primary screening tests for cervical cancer in most countries with implemented screening programs is Pap cytology, where a smear is taken from the cervix, stained with a dye cocktail and assessed under a light microscope for neoplastic alterations. Pap screening requires advanced infrastructures and experience as it is characterized by multiple visits for diagnosis and treatment, because it has a low single-test sensitivity of between 55 to 80 % [6,7] and generates many equivocal results which need further work-up [8]. Before women are referred to treatment, classically by removal of the affected tissue (conization), the test is repeated, the cervix is assessed visually by colposcopy and diagnostic biopsies are taken. Overall Pap cytology-based screening has frequently proven challenging and unworkable in low-resource settings [9].
Different programs investigate and assess alternative approaches, particularly the use of visual screening methods, such as visual inspection with acetic acid (VIA), for precancer and cancer detection and the use of cryotherapy as a pre-cancer treatment method. This is optimally achieved in a single visit and can be carried out also by competent non-physicians, including nurses and midwives. Because the diagnostic accuracy of VIA is largely heterogeneous, in some setting only reaching a sensitivity of~40 % [10] and thereby missing women with pre-cancer that would need treatment, still alternative tests suited for rural and limited resource conditions are currently designed and should be scientifically evaluated.
Detecting the viral DNA is a highly sensitive test for cervical cancer early detection, detecting more premalignant alterations than Pap cytology, used in addition to Pap cytology in certain settings and currently introduced as an alternative for primary screening in many industrialized countries [11]. However, considering the high prevalence of HPV infections, particularly in young women, detecting HPV DNA is a poorly specific test for real cellular alterations and therefore requires additional triage tests for the specific identification of women needing further work-up or treatment [12]. Much effort is currently spent in evaluating the clinical performance of new biomarkers, in order to reduce referral rates, unnecessary treatments and finally costs. In developing countries new biomarkers are particularly attractive as potential point-of-care tests. They can be used to specifically identify directly at one visit those women that need treatment and may thereby reduce the lost-tofollow-up rate [13].
There are different biomarkers that have been identified and suggested to improve diagnosis of cervical cancer and its precancerous lesions. One promising marker is the cyclin dependent kinase inhibitor p16 INK4a , which becomes overexpressed in response to viral oncogene E7 expression [14]. A number of studies have investigated the clinical use of p16 INK4a as a specific biomarker for cells with transforming HPV infections [15]. HPV-transformed cells overexpress p16 INK4a but retain the capacity to proliferate and are thus double-positive for p16 INK4a and the proliferation marker Ki-67, while senescent cells express p16 INK4a but are Ki-67 negative [16]. An immunochemical test which in parallel detects p16 INK4a and the proliferation marker Ki-67 (p16 INK4a /Ki-67 cytology, CINtec PLUS) is designed for application on cytologic smears taken from the uterine cervix with a brush, spread on a glass slide, stained for expression of the two markers and assessed under a light microscope. The test demonstrated high sensitivity comparable to HPV DNA testing but superior specificity compared to HPV DNA testing in a European screening population [15,17].
The objective of the present study was to study overall positivity rates of p16 INK4a /Ki-67 cytology in a screening population of Kenyan women and compare it to VIA/VILI and HPV DNA testing. Additionally the study was designed to evaluate the diagnostic performance of the tests to detect high grade CIN.

Characteristics of the study population and proportion of positive VIA/VILI, HPV and p16 INK4a /Ki-67 results
A total of 498 women met the eligibility criteria. After exclusion of women with incomplete personal information (no age documented), no VIA/VILI and/or invalid laboratory results in either Pap cytology (low cell number), p16 INK4a /Ki-67 cytology (low cell number) and/or HPV DNA (no cell pellet), 477 samples remained for evaluation. Mean age of these 477 study participants was 35.6 years, ranging between 18 and 74 years (standard deviation 9.9 years). A detailed socio-demographic characterization of the study population is given in reference [18].
VIA/VILI was only positive in a total of 3.1 % (15/477) of the women with the highest prevalence in the age group 46 to 50 years (9.8 %, 4/41) and no positives in women younger than 21 or older than 55 years (Fig. 1

Performance of the tests to detect high grade cervical intraepithelial neoplasia
The histopathology of a biopsy is considered as the gold-standard for the diagnosis of cervical dysplasia. Women were invited to colposcopy and biopsy if at least one of the tests VIA/VILI, Pap cytology, HPV DNA, and/or p16 INK4a /Ki-67 was positive. Women with only negative test results were considered as disease negative. Of the 22 women which appeared for colposcopy, 4 had no visible lesion and were thus not biopsied, 8 had normal histology in the punch biopsies, 2 women had CIN1, 2 had CIN2 and 6 women were diagnosed with CIN3. All biopsies were evaluated independently from H&E evaluation for p16 INK4a expression and all CIN2 and CIN3 lesions showed positive diffuse p16 INK4a expression, while normal and CIN1 cases were p16 INK4anegative, thus supporting the diagnosis of high-grade dysplasia in 8 women (2 CIN2, 6 CIN3).
The 6 lesions diagnosed as CIN3 and the two lesions diagnosed as CIN2 in a punch biopsy were all not positive  (Table 1).

Discussion
The high incidence of cervical cancer in Kenya and other developing countries is amongst other reasons due to lacking opportunities for early detection followed by treatment of pre-invasive lesions when necessary.
Visual inspection (VIA and VILI) is used in some setting with variable sensitivity and specificity [10]. HPV DNA testing is being evaluated in developing countries as a more objective test with higher sensitivity and limited specificity [19]. The aim of the present study was to evaluate p16 INK4a /Ki-67 dual-stain cytology in a screening population of Kenyan women in comparison to HPV DNA testing and VIA/VILI. p16 INK4a is a marker with a potentially favorable diagnostic profile, i.e. low rate of false-positive test results and high detection rate of disease [17,20].
HPV DNA testing yielded the highest rate of overall positive results (20.9 %; 100/477) in our study with highest HPV prevalence in women younger than 21 years. Among women with available colposcopy and biopsy HPV DNA testing detected all women with histologically confirmed high grade lesions (n = 8), but was also positive in 91.7 % (11/12) of women with normal histology. p16 INK4a /Ki-67 cytology yielded a lower overall rate of positive results (8.2 %; 39/477) and most importantly no positives in women younger than 21 years. This indicates that the test does not pick up the many transient and non-transforming HPV infections in this age group that most likely do not need to be treated. Furthermore p16 INK4a /Ki-67 cytology was positive in all 6 women with CIN3 lesions, in one of the two CIN2 lesions and in only 8.3 % (1/12) of women with normal histology in the punch biopsy.
In our study p16 INK4a /Ki-67 cytology staining was performed in an experienced laboratory in Heidelberg, Germany. However, the availability as ready-to-use reagents and little technical equipment which is required might give the opportunity to implement it in an environment with less advanced infrastructure. We used the PreservCyt ThinPrep system for cytology preparations in the study as this allowed to use one cervical swab for all tests. However, p16 INK4a /Ki-67 cytology staining can also be performed on conventional cytology smears. There is no published data on direct comparison of p16 INK4a /Ki-67 cytology using both cytologic methods (liquid-based vs conventional) for the same woman; there was however no significant difference in p16 INK4a /Ki-67 cytology performance between women screened with conventional smears compared to women screened with liquidbased cytology demonstrated in a large European primary screening study [17].
In the present study we solely evaluated the diagnostic performance of the tests; we however would like to point out that there is an urgent need now to complement diagnostic studies by well-designed cost-effectiveness analyses. Presently p16 INK4a /Ki67, particularly in combination with the ThinPrep system cannot be regarded as affordable for low-resource settings. On the long run however costeffectiveness will largely depend on incentives of ministries, industry and finally the performance of the used tests. In this regard the present study may add an important data set for upcoming initiatives and cost analyses.
VIA/VILI, which is currently used in some regions in developing countries, detected none of the women with histologically proven CIN2+, thus women would have been missed by the test. VIA/VILI has the advantage that it is cheap, requires no advanced equipment and can be used as a point-of-care test allowing for screening and cryotherapy if necessary on the same day. However its diagnostic performance can be poor, as indicated by our result.

Conclusions
Although the sample size is limited by the low number of women which followed the invitation to colposcopy and biopsy, it is a promising finding that p16 INK4a /Ki-67 testing yielded a similar detection rate of CIN2+ and a substantially lower rate of positive tests in women with negative histology compared to HPV DNA. Moreover, the overall lower test positivity rate particularly in young women of p16 INK4a /Ki-67 compared to HPV DNA testing suggests that only little transient infections are picked up and warrants further evaluation of the test in countries with high HPV prevalence. p16 INK4a /Ki-67 cytology can be performed within 5 hours manually and does not necessarily require technical equipment except a heating bath and a microscope, thus potentially being performed at a health facility within one day under standardized and controlled conditions. Assessing the slides does not require morphological interpretation, positive are considered all slides with one or more cells expressing both markers, p16 INK4a and Ki-67. This can be learned in a brief training session even by people without prior cytologic or pathologic training [21]. For further studies also automated software-based evaluations of the slides are well conceivable [22].

Study design
The rate of positive test results and diagnostic performance of VIA/VILI, HR-HPV DNA detection and p16 INK4a /Ki-67 dual-stain cytology was evaluated in a cross-sectional study in women living in Thika district, Kenya. Liquid-based cytology (LBC) samples were taken and sent to Heidelberg, Germany, where HR-HPV DNA testing and p16 INK4a /Ki-67 immunostaining was performed. Additionally, Pap staining was performed from the LBC sample in Heidelberg. According to the study protocol, women with a positive VIA/VILI and/or HR-HPV and/or p16 INK4a /Ki-67 test, and/or Pap cytology result were invited for colposcopy/biopsy to obtain a histopathologic diagnosis followed by treatment in cases were indicated. With the limitation that a sole positive HR-HPV DNA test only resulted in immediate colposcopy in women older than 30 years.
Ethical approval was obtained from the National Ethical Review Committee at the Kenya Medical Research Institute and women who agreed to participate signed an informed consent form.

Recruitment of women and cervical sampling
Women were recruited for the study in Thika District, Kenya in February 2010. The population is both rural and urban. Women who live in this region were invited to participate in the study through posters placed at markets places, churches, and health centers. Women were eligible for the study if they were (a) self-identified as residing in the region, (b) were ages 18 and above, (c) had an intact uterus, (d) did not report the use of vaginal medication for the previous two days, (e) did not report treatment for cervical disease for the previous 6 months, and (f) were not pregnant at the time of the study.
Cervical cells were collected by female nurses using the liquid-based cytology ThinPrep® Pap test Kit (Hologic, Bedford, USA) according to manufacturer's instruction and stored in the PreservCyt solution vial (Hologic, Bedford, USA) at ambient temperature. All tests, Pap cytology, p16 INK4a /Ki-67 cytology, and HR-HPV DNA detection were performed from the same vial at the Department of Applied Tumor Biology, Heidelberg, Germany. VIA/VILI was performed by the nurses after the cytology sample was taken and documented in a standard form.

Pap cytology
ThinPrep® slides were stained according to routine Pap staining laboratory protocols. All Pap cytology slides were read blinded to all other results at the Institute of Pathology, A2, Mannheim, Germany by an experienced cytotechnologist and gyneco-pathologist. The result was reported according to the Bethesda system.

High-risk human papillomavirus detection
After processing for cytology, four mls of residual Pre-servCyt® solution was used for HR-HPV detection. The HR-HPV detection was carried out using the Hybrid capture 2® (hc2) test (Qiagen, Hilden, Germany) according to the manufacturer's instructions. A positive hc2 result was defined as RLU/Co ≥ 1.

Colposcopy, biopsy and histology
Colposcopy was performed at Thika District Hospital by an experienced gynecologist. Four to five punch biopsies were taken from the cervix of women with visible lesions. The tissue was placed in formalin and embedded in paraffin for hematoxylin & eosin staining. The slides were assessed by an experienced pathologist at Institute of Pathology, A2, Mannheim, Germany. A second section from all biopsies was stained immunohistochemically for p16 INK4a (CINtec histology, mtm Laboratories, Heidelberg) and slides with a diffuse p16 INK4a expression beginning in the basal and parabasal cell layers were considered as p16 INK4a histology positive.

Data evaluation and disease endpoint
Results were computed as number of positive and negative test results in the entire study cohort, in different age groups and separated for cyologic and histologic diagnosis. Inter-assay agreements were assessed using Cohen's kappa statistics. Women with negative VIA/VILI, HPV DNA, p16 INK4a / Ki-67 and Pap cytology test were considered as disease negative. Women with a positive VIA/VILI and/or HR-HPV and/or p16 INK4a /Ki-67 test, and/or Pap cytology result were invited for colposcopy/biopsy to obtain a histopathologic diagnosis (CIN2, CIN3+). Women who showed up for colposcopy but had a normal appearing cervix were not biopsied and were considered as disease negative. Since most women with positive screening test results did not show up for colposcopy as per protocol, a gold standard disease endpoint for the evaluation of the diagnostic performance of the tests was only available for a subset of study participants. Prevalence of positive test results and agreements of the different tests was assessed in the entire study population.

Competing interests
MvKD was shareholder and member of the supervisory board of mtm Laboratories AG at the time the study was conducted.
Authors' contributions CWN designed the study, carried out the data collection, participated in data analyzes and interpretation, and drafted the manuscript. DS carried out data collection. KW designed the study and carried out the data collection. HB designed the study and carried out the data collection. PW designed the study and carried out the data collection. AM designed the study and carried out the data collection. JM designed the study and carried out the data collection. MvKD designed the study and participated in data interpretation. MR designed the study, participated in data analyzes and interpretation, and drafted the manuscript. All authors read and approved the final manuscript.